Stevanato Group
STVN
19.44
-0.42
-2.11%
Stevanato Group
US · STVN
#2012 by market cap
Listed 2021
19.44
-0.42
-2.11%
Live - 5344 symbols - heartbeat 145s ago
· 2026-10-08 07:00
Pre-market
19.95
+2.62%
After-hours
19.44
0.00%
Overnight
19.44
0.00%
- Market cap
- 5.31B
- P/E (TTM)i
- 35.41
- P/Bi
- 3.06
- EPSi
- 0.57
- Div yieldi
- 0.32%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on STVN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.47, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +7.45% YoY
Margins
- Gross margin
- 28.99%
- Operating margin
- 16.76%
- Net margin
- 11.79%
Key ratios & quality
- Enterprise valuei
- 5.64B
- Altman Z-Scorei
- 4.47
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | 536.54M | 662.04M | 843.92M | 983.68M | 1.09B | 1.10B | 1.19B |
| Gross profit | -- | 138.02M | 194.18M | 265.41M | 319.80M | 339.89M | 302.32M | 343.88M |
| Selling & admin expenses | -- | 76.71M | 78.91M | 82.95M | 111.83M | 104.90M | 109.13M | 119.06M |
| Research & development | -- | 7.83M | 17.39M | 29.62M | 34.39M | 35.67M | 31.67M | 25.44M |
| Operating profit | -- | 62.22M | 103.11M | 162.23M | 192.43M | 200.72M | 161.14M | 198.80M |
| Pretax profit | -- | 54.71M | 96.28M | 165.67M | 187.64M | 189.55M | 160.29M | 189.11M |
| Tax | -- | 16.01M | 17.68M | 31.40M | 44.63M | 43.86M | 42.52M | 49.28M |
| Net profit | -- | 38.71M | 78.60M | 134.27M | 143.02M | 145.69M | 117.77M | 139.83M |
| Basic EPS | -- | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
| Diluted EPS | -- | 0.13 | 0.27 | 0.53 | 0.54 | 0.55 | 0.43 | 0.51 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 256.60M | 280.04M | 303.17M | 346.48M | 273.60M | 302.00M |
| Gross profit | 69.89M | 78.59M | 88.50M | 106.90M | 75.20M | 86.81M |
| Selling & admin expenses | 27.81M | 32.09M | 30.85M | 25.66M | 32.00M | 31.75M |
| Research & development | 5.93M | 6.05M | 7.65M | 5.81M | 5.80M | 6.21M |
| Operating profit | 34.63M | 41.37M | 52.72M | 70.08M | 38.80M | 51.28M |
| Pretax profit | 35.11M | 39.11M | 49.13M | 65.76M | 39.20M | 38.12M |
| Tax | 8.60M | 9.41M | 13.07M | 18.21M | 11.20M | 15.16M |
| Net profit | 26.51M | 29.70M | 36.06M | 47.55M | 28.00M | 22.96M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.10 | 0.11 | 0.13 | 0.17 | 0.10 | 0.08 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 394.89M | 449.58M | 492.77M | 865.97M | 845.78M | 861.89M | 880.12M | 943.35M |
| Cash & ST investments | 114.66M | 126.27M | 157.12M | 438.21M | 256.65M | 70.35M | 98.27M | 130.60M |
| Inventory | 98.61M | 131.88M | 139.37M | 148.92M | 213.25M | 255.32M | 245.22M | 268.25M |
| Total assets | 781.58M | 882.18M | 967.98M | 1.42B | 1.66B | 2.07B | 2.33B | 2.54B |
| Total current liabilities | 243.91M | 262.94M | 316.18M | 338.62M | 462.50M | 574.39M | 477.47M | 535.88M |
| Short-term debt | 54.66M | 70.23M | 68.89M | 42.73M | 69.96M | 141.44M | 111.93M | 121.75M |
| Long-term debt | 245.19M | 284.18M | 273.94M | 183.99M | 133.75M | 242.05M | 305.23M | 337.78M |
| Total liabilities | 550,183,000.00 | 616,740,000.00 | 657,839,000.00 | 577,183,000.00 | 663,788,000.00 | 938,931,000.00 | 924,434,000.00 | 1,057,453,000.00 |
| Total equity | 231.40M | 265.44M | 310.14M | 841.66M | 995.91M | 1.13B | 1.40B | 1.49B |
| Retained earnings | -- | -- | -- | -- | 623.35M | 757.86M | 863.44M | 990.43M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 845.47M | 860.75M | 884.47M | 943.35M | -- | 932.74M |
| Cash & ST investments | 90.72M | 94.17M | 113.33M | 130.60M | -- | 83.58M |
| Inventory | 261.66M | 274.07M | 274.69M | 268.25M | 294.40M | 309.00M |
| Total assets | 2.32B | 2.35B | 2.41B | 2.54B | -- | 2.62B |
| Total current liabilities | 463.26M | 481.61M | 467.42M | 535.88M | -- | 578.26M |
| Short-term debt | 80.62M | 73.33M | 82.94M | 121.75M | -- | 123.95M |
| Long-term debt | 302.02M | 331.60M | 358.04M | 337.78M | -- | 312.03M |
| Total liabilities | 908,278,000.00 | 953,417,000.00 | 976,721,000.00 | 1,057,453,000.00 | -- | 1,068,905,000.00 |
| Total equity | 1.42B | 1.40B | 1.44B | 1.49B | 1.53B | 1.55B |
| Retained earnings | 890.85M | -- | -- | 990.43M | -- | 1.03B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -- | 42.57M | 155.66M | 133.34M | 103.31M | 105.21M | 155.78M | 286.08M |
| Depreciation & amortization | -- | 46.22M | 54.10M | 56.38M | 64.82M | 78.48M | 80.65M | 88.57M |
| Free cash flow | -- | -31.33M | 59.65M | 20.16M | -139.82M | -336.72M | -157.80M | 11.05M |
| Dividends paid | -- | -6.17M | -8.90M | -11.20M | -13.50M | -14.29M | -14.46M | -14.74M |
| Stock buybacks / issuance | -- | -- | 0 | 380.09M | 0 | 0 | 169.77M | 0 |
| Ending cash balance | -- | 85.39M | 115.60M | 411.04M | 228.74M | 69.60M | 98.27M | 130.60M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 99.84M | 44.91M | 47.22M | 94.11M | -- | -- |
| Depreciation & amortization | 20.62M | 21.57M | 21.78M | 24.59M | -- | -- |
| Free cash flow | 28.05M | -15.36M | -1.17M | -485.00K | -- | -- |
| Dividends paid | -- | -- | -- | 0 | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 90.72M | 94.17M | 113.33M | 130.60M | -- | -- |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | 15.77 | 27.26 | 23.31 | 15.54 | 13.68 | 9.29 | 9.67 |
| ROA %i | -- | 4.71 | 8.49 | 11.26 | 9.28 | 7.81 | 5.35 | 5.74 |
| ROIC %i | -- | 7.24 | 12.64 | 15.67 | 12.64 | 10.81 | 7.23 | 7.59 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | 19.11 | 17.82 | 14.30 |
| EBIT margin %i | -- | 11.24 | 15.45 | 20.22 | 19.49 | 17.86 | 15.14 | 16.49 |
| FCF / sales %i | -- | -- | 9.01 | 2.39 | -- | -- | -- | 0.93 |
| Current ratioi | 1.62 | 1.71 | 1.56 | 2.56 | 1.83 | 1.50 | 1.84 | 1.76 |
| Quick ratioi | 1.21 | 1.21 | 1.12 | 2.12 | 1.35 | 1.03 | 1.32 | 1.25 |
| Debt / assetsi | 40.57 | 42.58 | 37.50 | 17.22 | 13.16 | 19.14 | 18.42 | 18.43 |
| LT debt / equityi | 113.32 | 115.05 | 94.73 | 23.94 | 14.90 | 22.53 | 22.58 | 23.35 |
| Interest coveragei | -- | 10.76 | 17.06 | 34.31 | 47.47 | 44.93 | 24.35 | 30.17 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 22.39 | 17.91 | 9.37 | 6.44 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | 53.88 | 22.87 | -4.29 | -0.71 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 9.14 | 9.89 | 10.19 | 9.67 | 9.59 | 9.13 |
| ROA %i | 5.53 | 5.72 | 5.82 | 5.74 | -- | 5.42 |
| ROIC %i | 7.35 | 8.03 | 8.16 | 7.59 | 9.78 | 7.24 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 15.69 | 17.57 | 16.73 | 16.49 | 16.72 | 16.17 |
| FCF / sales %i | -- | -- | -- | 0.93 | -- | -- |
| Current ratioi | 1.83 | 1.79 | 1.89 | 1.76 | -- | 1.61 |
| Quick ratioi | 1.25 | 1.19 | 1.29 | 1.25 | -- | 1.08 |
| Debt / assetsi | 16.92 | 17.65 | 18.65 | 18.43 | -- | 16.92 |
| LT debt / equityi | 22.09 | 24.44 | 25.56 | 23.35 | -- | 20.59 |
| Interest coveragei | 26.10 | 9.34 | 24.95 | 30.17 | 25.29 | 34.07 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Biopharmaceutical and Diagnostic Solutions is the largest reported line at 88.24% of revenue, across 3 reported segments.
- The next-largest line, Engineering, is a distant second at 19.55% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Biopharmaceutical and Diagnostic Solutions88.24%
Engineering19.55%
Quote time 2026-10-08 07:00:16 · For reference only, not investment advice and not tailored to your situation.